跳至主要内容
临床试验/NCT05758064
NCT05758064招募中2 期

How to Rescue Hormonal Replacement Frozen Embryo Transfer Cycle With Low Serum Progesterone? A Randomized Control Trial.

El Shatby University Hospital for Obstetrics and Gynecology2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2023年1月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
发起方
入组人数
120
试验地点
2
主要终点
Clinical pregnancy rate

研究概览

简要总结

Frozen embryo transfer (FET) is increasingly adopted strategy in modern IVF. Among the many factors that have contributed to such change, the pursuit of an ovarian hyperstimulation syndrome free clinic has been strongly required. Improvements in the vitrification and warming processes and the excellent cryo-survival rates have turned FET in our main tool for preventing this complication. Moreover, a freeze all strategy has proven to provide excellent or even better pregnancy rates (PRs), not only in high but also in normal responders.

While ART have rapidly evolved in the areas of embryo culture, vitrification and understanding of the embryo development, little progress has been achieved regarding endometrial preparation for FET. Undoubtedly, correct implantation requires a good quality embryo and a suitable decidualized endometrium. Artificial cycles require hormone replacement treatment (HRT) with estradiol and progesterone (P4). However, there is not a single standardized treatment described for optimal endometrial preparation and no protocol has proven superiority in terms of reproductive outcomes.(5, 6) Although artificial preparation is the most convenient method to schedule FET cycles, recent reports have highlighted a potentially detrimental effect of low P4 levels prior to FET on miscarriage and live birth rates (LBRs). These results have been observed both in homologous and oocyte recipient FET cycles(7, 8), but also in FET cycles of embryos that had undergone PGT for aneuploidies (PGT-A).(9) Additional P4 supplementation may be a way to improve reproductive outcomes in these patients.

Our open labelled randomized control study aims to investigate whether patients with low serum P4 levels the day before FET under standard HRT can benefit in terms of clinical and ongoing pregnancy and implantation rates from an individualized luteal phase support consisting in the addition of oral dydrogesterone supplementation or daily subcutaneous P4 injection.

详细描述

A randomized control trial which will be conducted at El-Shatby University Maternity Hospital and private two private ART centres in Alexandria, Egypt.

120 patients in which HRT-FET cycles with low serum progesterone levels will divided into two groups :

  • Group A: 60 patients will be given oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily or,
  • Group B: 60 patients will be given subcutaneous injection 25mg daily (Prolutex®, IBSA).

METHODS Investigation Basal hormonal profile before initiation of treatment, a basal hormonal profile will be performed in all patients (basal FSH, LH, and estradiol levels) Pelvic ultrasound using a transvaginal probe, to assess ovaries, tubes and document uterine size, shape and endometrial thickness.

Endometrial preparation:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Patient prepared for frozen blastocyst transfer.
  • Maternal age ranges from less than 40 years.
  • BMI < 35kg/m
  • Normal uterine cavity.

排除标准

  • Uncorrected endometrial, uterine or pelvic pathology.
  • Recurrent implantation failure cases.
  • Patients suffering from recurrent miscarriages.
  • Male factor infertility due to azoospermia

研究组 & 干预措施

Oral dydrogesterone

Active Comparator

60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be given oral 10 mg dydrogesterone (Duphaston®, Abbott) twice daily

干预措施: Duphaston (Drug)

subcutaneous progesterone

Active Comparator

60 patients in HRT frozen embryo transfer with low serum progesterone less than 10 ng/ml 24 hours before the embryo transfer will be subcutaneous injection 25mg daily (Prolutex®, IBSA).

干预措施: prolutex (Drug)

结局指标

主要结局

Clinical pregnancy rate

时间窗: at the 6 th weeks of pregnancy

percentage of cases in which observation of a gestational sac with fetal heart beat by transvaginal ultrasound at 6 weeks of pregnancy

次要结局

  • Serum progesterone level on the day of FET(on the day of embryo transfer(before transfer))
  • Implantation rate(at the 6 th week of pregnancy)
  • Ongoing pregnancy rate(At the 20 th week of gestation)

研究者

发起方
El Shatby University Hospital for Obstetrics and Gynecology
申办方类型
Other
责任方
Principal Investigator
主要研究者

Aly Hussein

Principal investigator

El Shatby University Hospital for Obstetrics and Gynecology

研究点 (2)

Loading locations...

相似试验